

Plasma tissue factor in coronary artery disease. Further step to the understanding of the basic mechanisms of coronary artery thrombosis.

¹Vojacek Jan, ¹Dusek Jaroslav, ¹Bis Josef, ¹Stasek Josef and ²Blazek Martin

¹Department Medicine I and ²Department Medicine II, Charles University in Prague, Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove, Czech Republic

Mailing address: Jan Vojacek, MD, FESC, FACC

Department Medicine I

University Hospital

500 05 Hradec Kralove

Czech Republic

Tel.: ++ 420 495 832248

Fax: ++ 420 495 832006

E-mail: vojacjan@fnhk.cz

Short title: Tissue factor in coronary artery disease

This paper was supported by the Research Grant IGA NR/8131-3.

Summary:

Tissue factor is a cell surface protein that is expressed constitutively by monocytes, macrophages and fibroblasts, but also by some other cells in response to a variety of stimuli. The main function of tissue factor is to form a complex with factor VII/VIIa that converts factors IX and X to their active forms. Tissue factor is also involved in the pathophysiology of systemic inflammatory disorders, coagulopathies, atherosclerotic disease, tumor angiogenesis and metastasis. Increased tissue factor expression either locally in the coronary plaques or systematically on the circulating blood elements of patients with acute coronary syndromes may be responsible for increased thrombin generation, thus leading to the platelets activation and fibrin formation. Tissue factor therefore plays a pivotal role in the initiation of thrombotic complications in patients with coronary artery disease.

Keywords: Coronary artery disease; Coronary thrombosis; Tissue factor

Tissue factor and coagulation

Tissue factor is a cell surface protein that is expressed constitutively by monocytes, macrophages and fibroblasts (Mackman *et al.* 1991, Taubman *et al.* 1993, Kamimura *et al.* 2004, Penn *et al.* 1999). Some authors describe tissue factor expression also by cardiomyocytes (Mumford and McVey 2004). Tissue factor forms a complex with factor VII/VIIa that converts factors IX and X to their active forms. Blood borne tissue factor has been discovered recently. TF, however, may be expressed also in some other cell types in response to variety of stimuli. The initiation phase of thrombus generation begins when the disruption of vessel wall or atherosclerotic plaques exposes tissue factor to circulating factor VII, thus leading to the activation of both the intrinsic and extrinsic blood coagulation cascades (Rosenberg and Aird 1999). Tissue factor also induces cell signaling by stimulating G-protein-coupled protease activated receptors (PARs). Signaling pathways initiated by both TF / VIIa complex protease activation of PARs and phosphorylation of the tissue factor cytoplasmic domain appear to regulate different cellular functions (Rao and Pendurthi 2005). In normal arteries, tissue factor expression is limited to the adventitia except for sporadic expression in the media (Wilcoxon *et al.* 1989). A small quantity of circulating tissue factor is present in both the whole blood and serum of healthy individuals (Giesen PL and Nemerson 2000). Tissue factor is also involved in the pathophysiology of systemic inflammatory disorders, coagulopathies, atherosclerotic disease, chronic renal failure (Zemanova *et al.* 2003), tumor angiogenesis and metastasis (Price *et al.* 2004). There is a significant positive correlation between tissue factor level and serum creatinine, glycemia, LDL cholesterol, number of cigarettes smoked per day (Sambola *et al.* 2003) and an inverse correlation between tissue factor level and serum insulin (Zemanova *et al.* 2003).

Tissue factor in coronary artery disease

Inappropriate expression of tissue factor may result in thrombosis contributing to acute clinical consequences of coronary artery disease. Experimental data show that atheromatous plaques contain a high concentration of tissue factor relative to surrounding tissue (Marmur *et al.* 1996). Abundant tissue factor is also found in atheromatous lesions within foamy macrophages in macrovascular disease in humans such as aortic aneurysms and carotid arteries (Wilcoxon *et al.* 1989). Ruptures of atheromatous plaques (usually multiple) expose tissue factor to circulating factor VII causing the initiation of a clot formation and may

consequently lead to an abrupt vessel closure and myocardial infarction. This can be demonstrated by the examination of tissue samples obtained from patients with acute coronary syndromes, where higher levels of tissue factor are present in these lesions. In this way, tissue factor may play not only the role in the development of acute coronary syndromes but also in the progression of coronary artery disease (Annex *et al.* 1995, Ardissino *et al.* 1997, Mann and Davies 1999, Westmuckett *et al.* 2000) [via the tissue factor-dependent intramural fibrin deposition after plaque rupture and subsequent progression of the atherosclerotic lesion (Westmuckett *et al.* 2000)]. Modified ELISA (Westmuckett *et al.* 2000) and a rabbit polyclonal antibody against the solubilized tissue factor activity (Thiruvikraman *et al.* 1996) were used for in situ localization of tissue factor in human atherosclerotic plaques. Quantitation of tissue factor antigen was done to test the hypothesis that thrombin generation takes place directly in the atherosclerotic lesion (Thiruvikraman *et al.* 1996). This findings support the possible role of the tissue factor - dependent coagulation pathway in the intramural fibrin deposition and the progression of the atherosclerotic lesions.

Detached endothelial cells as well as microparticles from endothelial cells monolayers express tissue factor activity and this activity is markedly inhibited by microparticle-associated tissue factor pathway inhibitor (Kushak *et al.* 2005).

Apart from the role tissue factor has in the acute coronary syndromes, tissue factor expression has a potential role in vascular remodeling after coronary angioplasty. Cell culture studies have demonstrated that the TF / VIIa complex is critical for smooth muscle cell migration (Siegbahn *et al.* 2000). Furthermore, TF / VIIa - mediated smooth muscle cell migration can be inhibited by the overexpression of the tissue factor pathway inhibitor. The links between lipoproteins and tissue factor expression, and tissue factor and vascular remodeling, as demonstrated by Singh *et al.* (Singh *et al.* 2001), could offer a potential mechanism for the surprisingly early benefits of high-dose statin therapy in patients with acute coronary syndrome. Alternatively, because C-reactive protein has been shown to induce tissue factor expression in monocytes, statin therapy could be beneficial by decreasing CRP levels in these patients (Cermak *et al.* 1993).

Heparin treatment is associated with a decrease in tissue factor plasma levels and monocyte procoagulant activity (Gori *et al.* 1999) as well as with increased plasma level of the tissue factor pathway inhibitor.

Arnaud E *et al.* (Arnaud *et al.* 2000) investigated whether individual differences in tissue factor gene expression could predispose subjects to thrombosis. They sequenced the 5' domain of the gene and found 6 different polymorphisms. Genotyping of patients with

myocardial infarction in a case-control study involving 2354 subjects showed no association between the polymorphisms and nonfatal coronary thrombosis (Arnaud *et al.* 2000).

Many studies demonstrated elevated tissue factor plasma levels in patients with myocardial infarction (Saigo *et al.* 2001), stable angina (Kim *et al.* 2000), unstable angina and an increased risk for unfavorable outcomes in patients with unstable angina and raised tissue factor levels. Other authors found only an insignificant trend to raised plasma levels of tissue factor in patients with acute myocardial infarction and unstable angina pectoris as compared to patients with stable coronary artery disease and normal subjects (Maly *et al.* 2003). Tissue factor could be useful for the evaluation of the effect of cardiovascular risk intervention, but results in this field are still controversial (Lim *et al.* 2004). Can tissue factor also be used as a prognostic marker in patients with cardiovascular disease? Seljeflot (Seljeflot *et al.* 2003) followed patients after myocardial infarction for 4 years. Patients who had suffered an endpoint event (reinfarction or stroke) had significantly higher tissue factor levels as compared to those who did not. Other authors (Sambola *et al.* 2003, Lim *et al.* 2004) reported higher plasma levels of tissue factor in patients with diabetes than in control subjects. They suggest that higher levels of tissue factor may be the mechanism responsible for the increased thrombotic complications associated with the presence of other cardiovascular risk factors. No significant differences were found between diabetics and non-diabetics in patients with chronic renal failure (Zemanova *et al.* 2003).

Diagnostic tests for plasma tissue factor

The plasma level of tissue factor may be determined by means of the commercially available IMUBIND® Tissue Factor ELISA Kit (American Diagnostica, Inc.). The kit employs a murine anti-human tissue factor monoclonal antibody for antigen capture. Plasma samples are incubated in microtest wells precoated with capture antibody. Once captured, the tissue factor is detected using a biotinylated antibody fragment that specifically recognizes the bound tissue factor. The subsequent binding of horseradish peroxidase conjugated streptavidin completes the formation of the antibody-enzyme detection complex. Quantitative data are obtained by measuring the solution absorbance at 450 nm and relating it to the standard curve. The detection limit of this assay is around 10 pg/ml.

Tissue factor may circulate in the blood incorporated in pro-coagulant microparticles shedded as membrane vesicles (Mallat *et al.* 1999). Moreover, a form of human tissue factor generated by alternative splicing has been identified (Bogdanov *et al.* 2003). Alternatively spliced human tissue factor is soluble, circulates in the blood, exhibits pro-coagulant activity when exposed

to phospholipids, and is incorporated into thrombi and thus may contribute to thrombus growth (Bogdanov *et al.* 2003). Plasma tissue factor activity not associated with cells or microparticles is also being studied. Tissue factor-dependent generation of factor Xa on cryosections was used to assess the functional activity of the tissue factor (Thiruvikraman *et al.* 1996).

To employ tissue factor as a useful marker of atherothrombosis, a very sensitive diagnostic test for its detection and quantitation is needed. High-affinity antibodies are employed in the improved version of ELISA diagnostic tests for tissue factor plasma level assessment (Chen *et al.* 2005). The new assays provide higher sensitivity with much lower detection limit than currently available diagnostic sets. Data obtained by these assays show also markedly reduced individual variation. Higher sensitivity in tissue factor detection is of critical value especially in the group of patients with normal or slightly above-normal tissue factor levels and opens a new field for research. It is very important to detect accurately also low levels of tissue factor in order to use tissue factor as a potentially useful tool for risk stratification in patients with cardiovascular disease.

However, the question how to interpret an elevated tissue factor levels still remains unanswered. Additional investigations will be necessary for better acceptance of tissue factor as an independent biomarker for cardiovascular risk that we can incorporate into decision-making algorithms. We should not ignore the limited specificity with elevated tissue factor levels in a variety of different clinical situations. Larger scale clinical studies should confirm tissue factor independent significance.

References:

- ANNEX BH, DENNING SM, CHANNON KM. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. *Circulation* **91**: 2839-2843, 1995.
- ARDISSINO D, MERLINI PA, ARIENS R, COPPOLA R, BRAMUCCI E, MANNUCCI PM. Tissue factor antigen and activity in human coronary atherosclerotic plaques. *Lancet* **348**: 769-771, 1997.
- ARNAUD E, BARBALAT V, NICAUD V, CAMBIEN F, EVANS A, MORRISON C, ARVEILER D, LUC G, RUIDAVETS JB, EMMERICH J, FIESSINGER JN, AIACH M. Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies: Etude Cas-

- Temoins de l'Infarctus du Myocarde: Paris thrombosis case-control study. *Arterioscler Thromb Vasc Biol* **20**: 892–898, 2000.
- BOGDANOV VY, BALASUBRAMANIAN V, HATHCOCK J, VELE O, LIEB M, NEMERSON Y . Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. *Nature Medicine* **9**: 458 – 462, 2003.
- CERMAK J, KEY NS, BACH RR, BALLA J, JACOB HS, VERCELLOTTI GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. *Blood* **82**:513-520, 1993.
- CHEN C, YANG Q, PATEL S, LEI Y, MCALEER L, SINGLETON LP, SOLTIS D, WANG B. Characterization of human tissue factor (TF)-specific monoclonal antibodies prepared using a rapid immunization protocol. *Hybridoma (Larchmt.)* **24**: 78-85, 2005.
- GIESEN PL, NEMERSON Y. Tissue factor on the loose. *Seminars in Thrombosis and Hemostasis* **26**: 379-384, 2000.
- GORI AM, PEPE G, ATTANASIO M, FALCIANI M, ABBATE R, PRISCO D, FEDI S, GIUSTI B, BRUNELLI T, COMEGLIO P, GENSINI GF, NERI SERNERI GG. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. *Thromb Haemost* **81**: 589-593, 1999.
- KAMIMURA M, BEA F, AKIZAWA T, KATUS A, KREUZER J, VIEDT C. Platelet-derived growth factor induces tissue factor expression in vascular smooth muscle cells via activation of Egr-1. *Hypertension* **44**: 944-51, 2004.
- KIM HK, SONG KS, PARK YS, YUN YS, SHIM WJ. Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. *Cardiology* **93**: 31-36, 2000.
- KUSHAK RI, NESTORIDI E, LAMBERT J, SELIG MK, INGELFINGER JR, GRABOWSKI EF. Detached endothelial cells and microparticles as sources of tissue factor activity. *Thromb Res* **116**: 409-19, 2005.
- LIM HS, BLANN AD, LIP GYH. Soluble CD40 ligand, soluble P-selektin, interleukin-6, and tissue factor in diabetes mellitus. *Circulation* **109**: 2524-2528, 2004.
- MACKMAN N, BRAND K, EDGINGTON TS. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. *J Exp Med* **174**: 1517-1526, 1991.
- MALLAT Z, HUGEL B, OHAN J, LESECHE G, FREYSSINET JM, TEDGUI A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. *Circulation* **99**: 348-53, 1999.

- MALY M, VOJACEK J, HRABOS V, KVASNICKA J, SALAJ P, DURDIL V. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome. *Physiol Res* **52**: 719-728, 2003.
- MANN J, DAVIES MJ: Mechanisms of progression in native coronary artery disease: Role of healed plaque disruption. *Heart* **82**: 265-268, 1999.
- MARMUR JD, THIRUVIKRAMAN SV, FYFE BS. Identification of active tissue factor in human atherosclerotic plaques in human coronary atheroma. *Circulation* **94**: 1226-1232, 1996.
- MUMFORD AD, MCVEY JH. Tissue factor in the myocardium evidence of roles in haemostasis and inflammation. *Dis Markers* **20**: 353-8, 2004.
- PENN MS, PATEL CV, CUI MZ, DICORLETO PE, CHISOLM GM. LDL increase inactive tissue factor on vascular smooth muscle cells surfaces: hydrogen peroxide activates cell surface tissue factor. *Circulation* **99**: 1753-59, 1999.
- PRICE GC, THOMPSON, KAM PCA. Tissue factor and tissue factor pathway inhibitor. *Anaesthesia* **59**: 483-492, 2004.
- RAO LV, PENDURTHI UR. Tissue factor-factor VIIa signaling. *Arterioscler Thromb Vasc Biol* **25**: 47-56, 2005.
- ROSENBERG RD, AIRD WC. Vascular-bed-specific hemostasis and hypercoagulable states. *N Engl J Med* **340**: 1555-1564, 1999.
- SAIGO M, ABE S, OGAWA M, YAMASHITA T, BIRO S, MINAGOE S, MARUYAMA I, TEI C. Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. *Thromb Haemost* **86**: 1197-1203, 2001.
- SAMBOLA A, OSENDE J, HATHCOCK J, DEGEN M, NEMERSON Y, FUSTER V, CRANDALL J, BADIMON JJ. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. *Circulation* **107**: 973-977, 2003.
- SELJEFLOT I, HURLEN M, ARNESEN H. Levels of soluble tissue factor related to future clinical events in patients with myocardial infarction. *Thromb Haemost* 1 Supplement: abstract P0495, 2003.
- SIEGBAHN A, JOHNNELL M, RORSMAN C, EZBAN M, HELDIN CH, RONNSTRAND L. Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. *Blood* **96**: 3452-3458, 2000.

SINGH R, PAN S, MUESKE CS, WITT T, KLEPPE LS, PETERSON TE, SLOBODOVA A, CHANG JY, CAPLICE NM, SIMARY RD. Role of tissue factor pathway in murine model of vascular remodeling. *Circ Res* **89**: 71-76, 2001.

TAUBMAN MB, MARMUR JD, ROSENFELD CL, GUHA A, NICHTBERGER S, NEMERSON Y. Agonist-mediated tissue factor expression in vascular smooth muscle cells: role of calcium mobilization and protein kinase C activation. *J Clin Invest* **91**: 547-552, 1993.

THIRUVIKRAMAN SV, GUHA A, ROBOZ J, TAUBMAN MB, NEMERSON Y, FALLON JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. *Lab Invest* **75**: 451-61, 1996.

WESTMUCKETT AD, LUPU C, GOULDING DA, DAS S, KAKKAR VV, LUPU F. In situ analysis of tissue factor-dependent thrombin generation in human atherosclerotic vessels. *Thromb Haemost.* **84**: 904-11, 2000.

WILCOXON JN, SMITH KM, SCHWARTZ SM, GORDON D. Localization of tissue factor in the normal vessel wall and the atherosclerotic plaque. *Proc Natl Acad Sci USA* **84**: 2839-2843, 1989.

ZEMANOVA P, OPATRNY K, OPATRNA S, VIT L, SEFRNA F, RACEK J. Tissue factor, its pathway inhibitor, and metabolic disturbances in long-term peritoneal dialysis. *Kidney Blood Press Res* **26**: 368-375, 2003.